CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Sales reflect continued strong growth in oncology and vaccines
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Subscribe To Our Newsletter & Stay Updated
